Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.